Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00585143 · ClinicalTrials.gov registry record · Phase 1
Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly
A Phase 1 study of Dyslipidemia, Renal Insufficiency, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 6
- Study locations
NCT00585143 is a Phase 1 study of Dyslipidemia, Renal Insufficiency that has completed, run by AstraZeneca. The registered enrollment target is 37 participants. The trial reports 6 study locations across 5 states.
The verdict
NCT00585143, a Phase 1 study of Dyslipidemia, Renal Insufficiency, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 6
- Study locations
Study Summary
Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly
Conditions Studied
Interventions
- DRUG Rosuvastatin
- DRUG ABT-335
Study Locations (6)
Florida
- Site Reference ID/Investigator# 6610 - Gainesville
- Site Reference ID/Investigator# 6738 - Miami
Minnesota
- Site Reference ID/Investigator# 7723 - Minneapolis
Tennessee
- Site Reference ID/Investigator# 7319 - Knoxville
Texas
- Site Reference ID/Investigator# 6928 - San Antonio
Virginia
- Site Reference ID/Investigator# 8280 - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00585143
The ClinicalTrials.gov registry entry for NCT00585143 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dyslipidemia, Renal Insufficiency appearing as the primary indexed condition, and to 2 interventions - of which Rosuvastatin is the first listed.
NCT00585143 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Florida, Minnesota, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00585143 about?
NCT00585143 is a clinical study titled "Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly". Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly
What is the current status of trial NCT00585143?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2008-01. Estimated completion is 2008-10.
What conditions does trial NCT00585143 study?
This clinical trial studies the following conditions: Dyslipidemia, Renal Insufficiency.
What interventions are being tested in trial NCT00585143?
The interventions under investigation include: Rosuvastatin (DRUG), ABT-335 (DRUG).
Who is sponsoring clinical trial NCT00585143?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00585143 being conducted?
This trial has 6 study locations across Florida, Minnesota, Tennessee, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.